1-(2-溴乙氧基)-4-氟苯 | 332-48-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(2-溴乙氧基)-4-氟苯
• 中文别名: 2-溴乙基4-氟苯基醚；4-氟苯氧基-乙基溴；2-(4-氟苯氧基)溴乙烷；β-溴-4-氟苯乙醚；4-氟苯氧基乙基溴
• 英文名称: 2-(4-fluorophenoxy)-ethylbromide
• 英文别名: 1-(2-bromoethoxy)-4-fluoro-benzene；1-(2-Bromoethoxy)-4-fluorobenzene
• CAS: 332-48-9
• 化学式: C₈H₈BrFO
• mdl: MFCD00044739
• 分子量: 219.053
• InChiKey: JXSPKRUNMHMICQ-UHFFFAOYSA-N

物化性质

• 熔点：
  58-60 °C
• 沸点：
  66°C/0.1mmHg(lit.)
• 密度：
  1.4901 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2909309090
• 安全说明：
  S24/25
• 危险性防范说明：
  P273
• 危险性描述：
  H302,H412
• 储存条件：
  室温且干燥环境中保存。

SDS

Name:	p-Fluorophenoxy-ethylbromide 95% Material Safety Data Sheet
Synonym:	1-(2-Bromoethoxy)-4-fluorobenzen
CAS:	332-48-9

Section 1 - Chemical Product MSDS Name:p-Fluorophenoxy-ethylbromide 95% Material Safety Data Sheet
Synonym:1-(2-Bromoethoxy)-4-fluorobenzen

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
332-48-9	4-Fluorophenoxy-ethylbromide	95	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Do not induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of milk or water. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. This material in sufficient quantity and reduced particle size is capable of creating a dust explosion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 332-48-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H8BrFO
Molecular Weight: 219.05

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, hydrogen fluoride gas, hydrogen bromide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 332-48-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Fluorophenoxy-ethylbromide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 332-48-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 332-48-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 332-48-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(2-溴乙氧基)-4-氟苯 在 盐酸 、 sodium hydroxide 、 甲酸 、 氯化亚砜 、 甲烷磺酸 、 乙酸酐 、 α-chymotrypsin 作用下， 以 盐酸 、 甲醇 、 水 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 sodium chloride 为溶剂， 反应 113.0h， 生成 索比尼尔
  参考文献：
  名称：

  Novel synthesis of the aldose reductase inhibitor sorbinil via amidoalkylation, intramolecular oxazolidin-5-one alkylation and chymotrypsin resolution

  摘要：

  DOI：

  10.1021/jo00392a017
• 作为产物：
  描述：

  4-氟苯酚 、 1,2-二溴乙烷 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 24.0h， 生成 1-(2-溴乙氧基)-4-氟苯
  参考文献：
  名称：

  发现1-芳氧基乙基哌嗪衍生物作为Kv1.5钾通道抑制剂（第一部分）

  摘要：

  Kv1.5钾通道是一种治疗房颤（AF）的有效且安全的治疗靶标，它是威胁人类的最常见心律不齐。本文中，通过从内部数据库中修改命中化合物7k，合成了48种衍生物，以通过全细胞膜片钳技术测定其Kv1.5抑制作用。选择了六种显示出比阳性化合物决奈达隆更好的效价的化合物用于其类药物性质的下一个评估。化合物8显示出平衡的溶解度和渗透性。它还显示出可接受的药效学特征，急性毒性非常低。考虑到所有这些数据，化合物8 可以作为开发用于治疗AF的新型治疗剂的有希望的先导。

  DOI：

  10.1016/j.ejmech.2014.03.075

文献信息

• Organophotoredox-Catalyzed Formation of Alkyl–Aryl and −Alkyl C–S/Se Bonds from Coupling of Redox-Active Esters with Thio/Selenosulfonates
  作者：Yue Dong、Peng Ji、Yueteng Zhang、Changqing Wang、Xiang Meng、Wei Wang

  DOI：10.1021/acs.orglett.0c03624

  日期：2020.12.18

  A mild organophotoredox synthetic protocol for forming a Csp3–S/Se bond by reacting widespread redox-active esters with thio/selenosulfonates has been developed. The power of the synthetic manifold is fueled by an unprecedented broad substrate scope and wide functional group tolerance.

  已经开发出一种温和的有机光氧化还原合成方案，通过使广泛的氧化还原活性酯与硫代/硒磺酸盐反应形成 C sp 3 –S/Se 键。前所未有的广泛底物范围和广泛的官能团耐受性推动了合成歧管的力量。
• Synthesis, antimicrobial evaluation, and in silico studies of quinoline—1H-1,2,3-triazole molecular hybrids
  作者：Paul Awolade、Nosipho Cele、Nagaraju Kerru、Parvesh Singh

  DOI：10.1007/s11030-020-10112-3

  日期：2021.11

  copper(I)-catalyzed azide-alkyne [3 + 2] dipolar cycloaddition reaction (CuAAC). Antimicrobial evaluation identified compound 16 as the most active hybrid in the library with a broad-spectrum antibacterial activity at an MIC80 value of 75.39 μM against methicillin-resistant S. aureus, E. coli, A. baumannii, and multidrug-resistant K. pneumoniae. The compound also showed interesting antifungal profile against C.

  摘要 抗菌素耐药性已成为对全球公共卫生的重大威胁，因此迫切需要具有改善治疗效果的新药。在这方面，分子杂交被认为是提供多靶点候选药物的可行策略。在此，我们报告了通过铜 (I) 催化的叠氮化物-炔烃 [3 + 2] 偶极环加成反应 (CuAAC) 合成的喹啉—1 H -1,2,3-三唑分子杂化物库。抗菌评估确定化合物16是文库中最活跃的杂合体，对耐甲氧西林金黄色葡萄球菌、大肠杆菌、鲍曼不动杆菌的 MIC 80值为 75.39 μM，具有广谱抗菌活性。和多重耐药肺炎克雷伯菌。该化合物还显示出有趣的抗白色念珠菌和新型念珠菌的抗真菌特性，MIC 80值分别为 37.69 和 2.36 μM，优于氟康唑。体外毒性分析显示对人红细胞 (hRBC) 无溶血活性，但对人胚胎肾细胞 (HEK293) 有部分细胞毒性。此外，计算机研究预测了优异的药物样特性以及三唑环在稳定与靶蛋白络合方面的重要性。总体而言，这些
• Regioselectivity of N-substitution in bis-alkylation of 1,2,4-triazolo[1,5-a]benzimidazole-2-thione
  作者：T. A. Kuz’menko、V. V. Kuz’menko、L. N. Divaeva、A. S. Morkovnik、G. S. Borodkin

  DOI：10.1007/s11172-012-0158-7

  日期：2012.6

  Cyclization of the corresponding N-substituted 1,2-diaminobenzimidazoles with carbon disulfide in refluxing DMF leads to 3-methyl- and 3-benzyl-1,2,4-triazolo[1,5-a]benzimidazole-2-thiones. Based on the results of their S-alkylation, quantum chemical calculations by the density functional theory method, and 1D and 2D NMR spectroscopic studies, it was concluded that the bis-alkylation of N-unsubstituted 1,2,4-triazolo[1,5-a]benzimidazole-2-thione in the presence of a base proceeds with the formation of N(4)-derivatives of 2-alkylthio-1,2,4-triazolo[1,5-a]benzimidazole, rather than N(3)-derivatives as was believed earlier.

  将相应的N-取代1,2-二氨基苯并咪唑与二硫化碳在回流的DMF中环化得到3-甲基和3-苄基-1,2,4-三唑并[1,5-a]苯并咪唑-2-硫酮。根据它们的S-烷基化结果、密度泛函理论方法的量子化学计算以及一维和二维核磁共振波谱研究，得出的结论是，在碱存在的条件下，N-未取代的1,2,4-三唑并[1,5-a]苯并咪唑-2-硫酮的双烷基化反应是通过形成2-烷硫基-1,2,4-三唑并[1,5-a]苯并咪唑的N(4)衍生物进行的，而不是像之前认为的那样形成N(3)衍生物。
• Prokineticin 1 receptor antagonists
  申请人：Coats Steven J.

  公开号：US20080269225A1

  公开（公告）日：2008-10-30

  The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.

  本发明涉及某些化合物的新颖结构，其化学式为（I）：以及制备这些化合物、组合物、中间体和衍生物的方法，以及用于治疗促动素1或促动素1受体介导的疾病的方法。
• [EN] CARBIDOPA PRODRUGS AND USES THEREOF<br/>[FR] PROMEDICAMEMTS DE CARBIDOPA ET LEURS UTILISATIONS
  申请人：XENOPORT INC

  公开号：WO2004052841A1

  公开（公告）日：2004-06-24

  Prodrugs of carbidopa, derivatives of carbidopa prodrugs, methods of making prodrugs of carbidopa and derivatives thereof, methods of using prodrugs of carbidopa and derivatives thereof, and compositions of prodrugs of carbidopa and derivatives thereof are disclosed.

  卡比多巴的前药、卡比多巴前药的衍生物、卡比多巴及其衍生物前药的制作方法、卡比多巴及其衍生物前药的使用方法以及卡比多巴及其衍生物前药的组合物被公开。